NanoViricides, Inc. (NYSE American: NNVC) has reported significant progress in the clinical development of its broad-spectrum antiviral candidate, NV-387 Oral Gummies, with the initiation of two Phase 2 trials for Ebola and mpox. The announcement, detailed in the company's quarterly report for the period ended September 30, 2026, underscores the potential of a single antiviral agent to address multiple high-consequence viral diseases, a strategy that could reshape preparedness and treatment paradigms for emerging infections.
Enrollment for the Ebola trial began on September 23, evaluating NV-387 against the Ebola Bundibugyo virus disease in the Democratic Republic of the Congo. The company has independently funded this trial and established on-site molecular diagnostic capabilities, reflecting its commitment to advancing treatments in regions where such infrastructure is often lacking. Simultaneously, a separate Phase 2 trial site opened the same day to assess NV-387 for mpox, further expanding the drug's clinical footprint. These developments highlight NanoViricides' ability to execute complex international trials and its focus on diseases with limited therapeutic options.
Beyond these infectious disease outbreaks, NanoViricides has received FDA Orphan Drug and Rare Pediatric Disease designations for NV-387 in the treatment of measles, granted in April and May 2026, respectively. These designations provide incentives such as market exclusivity and priority review, which could accelerate the development timeline and enhance the commercial viability of NV-387. The company plans to pursue a Phase 2 measles trial and seek nondilutive funding, including potential U.S. government grants, to support this effort. This strategic move aligns with global measles resurgence concerns and the need for novel antivirals.
The broader implications of NanoViricides' progress are substantial. NV-387 is being developed as a broad-spectrum antiviral with potential applications across RSV, COVID-19, influenza, and other respiratory infections, as well as MPOX/smallpox and measles. If successful, NV-387 could offer a first-line defense against multiple viral threats, reducing reliance on pathogen-specific treatments and simplifying stockpiling for public health emergencies. The company's use of its nanoviricide technology platform, licensed from TheraCour Pharma, positions it at the forefront of nanomedicine-based antiviral development.
Investors and industry observers can find more details in the full press release available at https://ibn.fm/HChFn. For ongoing updates on NanoViricides, the company's newsroom is accessible at https://ibn.fm/NNVC. Additionally, the company's website, www.nanoviricides.com, provides comprehensive information about its pipeline and technology. The announcement was disseminated through InvestorWire, a specialized communications platform known for wire-grade press release syndication. InvestorWire operates within the Dynamic Brand Portfolio of over 75 brands under IBN, which offers extensive reach including editorial syndication to 5,000+ outlets and social media distribution to millions of followers. These channels ensure that news like NanoViricides' clinical milestones reaches a wide audience of investors and stakeholders. As with all drug development, NV-387 remains investigational, and its safety and efficacy are under clinical evaluation. The path to regulatory approval is lengthy and requires substantial capital, but the progress to date signals a promising step toward addressing unmet medical needs in viral disease treatment.


